User:Tkadm30/Notebook/Brainstorming: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
No edit summary
Line 6: Line 6:
** retrograde 2-AG signaling may promote glutamatergic LTP. [https://www.ncbi.nlm.nih.gov/pubmed/23307660 PMID]
** retrograde 2-AG signaling may promote glutamatergic LTP. [https://www.ncbi.nlm.nih.gov/pubmed/23307660 PMID]
** retrograde 2-AG signaling is ATP-dependent [https://www.ncbi.nlm.nih.gov/pubmed/23018918 PMID]
** retrograde 2-AG signaling is ATP-dependent [https://www.ncbi.nlm.nih.gov/pubmed/23018918 PMID]
** non-retrograde TRPV1 activation by endogenous anandamide transporter (neuroprotective)
** neuron-astrocyte signaling

Revision as of 06:00, 10 July 2015

  • Important secondary messengers: NMDA, Dopamine, Serotonin, GABA, AChr, calmodulin, p38 MAP kinase
  • Sites of interests: p38 (MEK), EGFR (Fyn), c-Src homolog domain (brain/hippocampus/amygdala), Ras/Raf/MEK pathway (Bcl-2), NMDAR, NRG1
  • Cannabinoid agonists and the cholinergic system: Selective affinity for the mAChR receptor may indicates endogenous endocannabinoids as potential agents for neuroprotection agaisn't organophosphate-derived nerve gas precursors and Alzheimer disease. (EC 3.1.1.8)
  • Key roles for nanoparticles based chemical inducers and repressors are multiples and under intense research including but not limited to chemotherapy and bioinformatics.
  • Endocannabinoid transport
    • retrograde 2-AG signaling may promote glutamatergic LTP. PMID
    • retrograde 2-AG signaling is ATP-dependent PMID
    • non-retrograde TRPV1 activation by endogenous anandamide transporter (neuroprotective)
    • neuron-astrocyte signaling